Last checked at 31 Jan 2023 07:00
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Change of Adviser
Tissue Regenix (AIM: TRX), the regenerative medical device company, is pleased to announce the appointment of finnCap Ltd as its Nominated Adviser and Broker with immediate effect.
For more information:
Tissue Regenix Group plc | www.tissueregenix.com | |||||
David Cocke, Chief Financial Officer | Via Walbrook PR | |||||
| Tel: +44(0)20 7220 500 | |||||
Walbrook PR (Financial PR & IR) | Tel: +44(0)20 7933 8780 | |||||
Alice Woodings / Lianne Applegarth | TissueRegenix@walbrookpr.com | |||||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
AIM Rule 17 Disclosure
The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
David Cocke
Regarding the directorship disclosures made in David Cocke's announcement of appointment on 21 January 2021, Packaging Partners LC and NuPak Medical Ltd were announced as previous directorships (within the previous 5 years) when they were current directorships. In addition, David Cocke had been a partner of Talon Medical Ltd within the previous 5 years of his appointment to the Board of Tissue Regenix.
Jonathan Glenn
Regarding the disclosures made in Jonathan Glenn's announcement of appointment on 19 January 2016, the Company provides the following updates.
Mr. Glenn's full name was disclosed as Jonathan M Glenn. Mr. Glenn's full legal name is Jonathan Martin Glenn.
In addition to the current directorship of Consort Medical plc ("Consort Medical") that was disclosed at the time of his appointment, Jonathan Glenn was also a director of a number of subsidiaries of Consort Medical, as set out below:
AESICA BC Limited
AESICA Formulation Development Limited
AESICA Holdco Limited
AESICA M1 Limited
AESICA M2 Limited
AESICA Queensborough Limited
AESICA Trustee Company Limited
Bespak Europe Limited
Bespak Finance Limited
Bespak Holdings Limited
Consort Medical Finance 2010 Limited
Consort Medical Finance Limited
Consort Medical Limited
Integrated Aluminium Components Limited
Medical House (ASI) Limited
Medical House Products Limited
Pharmaron Manufacturing Services (UK) Ltd
The Medical House Group Limited
The Medical House Limited
Trevor Phillips
In addition to the directorship disclosures made in Trevor Phillip's announcement of appointment on 5 January 2021, Trevor Phillips had also held the following directorships within the previous 5 years:
Vectura Group Limited (previously Vectura Group plc)
Vectura Limited
Vectura Delivery Devices Limited
Shervanthi Homer-Vanniasinkam
In addition to the disclosures made in Shervanthi Homer-Vanniasinkam's announcement of appointment on 1 June 2016, the following directorships are disclosed:
Directorship held at time of appointment to Tissue Regenix: Holistx Limited
Directorship held within previous 5 years at time of appointment to Tissue Regenix: The Vascular Society